Treatment of Psoriasis with Efalizumab in Patients with Hepatitis C Viral Infection: Report of Five Cases. Dermatology (Basel, Switzerland) [Dermatology] Journal article | | Title | Treatment of Psoriasis with Efalizumab in Patients with Hepatitis C Viral Infection: Report of Five Cases. | | Author(s) | Gisondi P, Prignano F, Grossi P, Lotti T, Girolomoni G | | Institution | Section of Dermatology and Venereology, Department of Biomedical and Surgical Sciences, University of Verona, Verona, Italy. | | Source | Dermatology 2009 Jun 9. | | Abstract | Background: Concomitant hepatitis C virus infection (HCV) needs caution when selecting systemic treatments in psoriasis patients as some agents confer a risk of liver toxicity and/or are immunosuppressant. Phototherapy may provide a therapeutic choice but it is not always a practical option. Limited evidence supports the use of cyclosporine or TNF-alpha blockers. No data are available concerning the safety of efalizumab in patients with HCV infection.
Objective: To describe the clinical characteristics and evolution of 5 adult patients with severe chronic plaque psoriasis and concomitant HCV infection who were treated with efalizumab. Method: A retrospective clinical case report.
Results: Five adult patients with severe chronic plaque psoriasis and concomitant HCV infection were treated successfully using efalizumab with no increased viral replication and progression of liver disease for a follow-up of 8-20 months.
Conclusion: Although further confirmation is needed, this report provides preliminary evidence to support also a cautious use of efalizumab in patients with HCV infection. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19506351 |
|
|
| |
Advertise on this site.
| | |
|
